+

WO2003011309A3 - Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie - Google Patents

Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie Download PDF

Info

Publication number
WO2003011309A3
WO2003011309A3 PCT/EP2002/008154 EP0208154W WO03011309A3 WO 2003011309 A3 WO2003011309 A3 WO 2003011309A3 EP 0208154 W EP0208154 W EP 0208154W WO 03011309 A3 WO03011309 A3 WO 03011309A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
hypercholesterolaemia
treating
treating hypercholesterolaemia
treatment
Prior art date
Application number
PCT/EP2002/008154
Other languages
English (en)
French (fr)
Other versions
WO2003011309A2 (de
Inventor
Jobst Krauskopf
Erich Elstner
Original Assignee
S K Entpr Gmbh
Jobst Krauskopf
Erich Elstner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S K Entpr Gmbh, Jobst Krauskopf, Erich Elstner filed Critical S K Entpr Gmbh
Priority to EP02767244A priority Critical patent/EP1408992A2/de
Priority to AU2002331279A priority patent/AU2002331279A1/en
Publication of WO2003011309A2 publication Critical patent/WO2003011309A2/de
Publication of WO2003011309A3 publication Critical patent/WO2003011309A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)

Abstract

Offenbart wird die Verwendung einer Calciumverbindung zur Behandlung von Hypercholesterinämie und/oder zur Prophylaxe oder Behandlung von durch Hypercholesterinämie verursachten Krankheiten.
PCT/EP2002/008154 2001-07-20 2002-07-22 Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie WO2003011309A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02767244A EP1408992A2 (de) 2001-07-20 2002-07-22 Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie
AU2002331279A AU2002331279A1 (en) 2001-07-20 2002-07-22 Pharmaceutical composition for treating hypercholesterolaemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10135493.2 2001-07-20
DE10135493A DE10135493A1 (de) 2001-07-20 2001-07-20 Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie

Publications (2)

Publication Number Publication Date
WO2003011309A2 WO2003011309A2 (de) 2003-02-13
WO2003011309A3 true WO2003011309A3 (de) 2003-07-24

Family

ID=7692564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008154 WO2003011309A2 (de) 2001-07-20 2002-07-22 Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie

Country Status (4)

Country Link
EP (1) EP1408992A2 (de)
AU (1) AU2002331279A1 (de)
DE (1) DE10135493A1 (de)
WO (1) WO2003011309A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233229A1 (de) * 2002-07-22 2004-02-12 S.K. Enterprise Gmbh Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels
DE10331202A1 (de) * 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
EP3737363A4 (de) 2018-01-12 2021-10-20 Metimedi Pharmaceuticals Co., Ltd Verfahren zur behandlung chronisch entzündlicher erkrankungen

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1808173A1 (de) * 1967-11-15 1970-11-12 Nieper Dr Med Hans A Calciumorotat
JPS63198630A (ja) * 1987-02-13 1988-08-17 Kao Corp 脂質代謝改善剤
JPH04148651A (ja) * 1990-10-12 1992-05-21 Norihiro Kamata 鉄分とカルシウムを強化したこんにゃく
US5126150A (en) * 1990-10-01 1992-06-30 The Procter & Gamble Company Compositions containing psyllium
JPH05304928A (ja) * 1992-04-29 1993-11-19 Aroma Kagaku Kikai Kogyo:Kk カルシウム添加食品の製造方法
CN1167581A (zh) * 1997-07-09 1997-12-17 张永新 钙奶营养麦片
JPH1014534A (ja) * 1996-06-27 1998-01-20 Snow Brand Milk Prod Co Ltd 栄養組成物
CN1245021A (zh) * 1999-07-29 2000-02-23 王操 A、d钙奶茶
CN1259384A (zh) * 1999-01-06 2000-07-12 哈尔滨红太阳实业有限公司 牦牛骨髓壮骨粉及其加工方法
WO2000042024A1 (en) * 1999-01-09 2000-07-20 Astrazeneca Ab Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
CN1282536A (zh) * 2000-08-29 2001-02-07 刘国柱 胡萝卜银杏营养复合饮料配方及制作工艺
WO2001028999A1 (en) * 1999-10-18 2001-04-26 EGIS Gyógyszergyár Rt. Process for the preparation of amorphous atorvastatin calcium
US6403129B1 (en) * 1999-12-27 2002-06-11 Mac Farms, Inc. Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1808173A1 (de) * 1967-11-15 1970-11-12 Nieper Dr Med Hans A Calciumorotat
JPS63198630A (ja) * 1987-02-13 1988-08-17 Kao Corp 脂質代謝改善剤
US5126150A (en) * 1990-10-01 1992-06-30 The Procter & Gamble Company Compositions containing psyllium
JPH04148651A (ja) * 1990-10-12 1992-05-21 Norihiro Kamata 鉄分とカルシウムを強化したこんにゃく
JPH05304928A (ja) * 1992-04-29 1993-11-19 Aroma Kagaku Kikai Kogyo:Kk カルシウム添加食品の製造方法
JPH1014534A (ja) * 1996-06-27 1998-01-20 Snow Brand Milk Prod Co Ltd 栄養組成物
CN1167581A (zh) * 1997-07-09 1997-12-17 张永新 钙奶营养麦片
CN1259384A (zh) * 1999-01-06 2000-07-12 哈尔滨红太阳实业有限公司 牦牛骨髓壮骨粉及其加工方法
WO2000042024A1 (en) * 1999-01-09 2000-07-20 Astrazeneca Ab Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
CN1245021A (zh) * 1999-07-29 2000-02-23 王操 A、d钙奶茶
WO2001028999A1 (en) * 1999-10-18 2001-04-26 EGIS Gyógyszergyár Rt. Process for the preparation of amorphous atorvastatin calcium
US6403129B1 (en) * 1999-12-27 2002-06-11 Mac Farms, Inc. Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet
CN1282536A (zh) * 2000-08-29 2001-02-07 刘国柱 胡萝卜银杏营养复合饮料配方及制作工艺

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF INTERNAL MEDICINE, vol. 152, no. 12, 1992, pages 2441 - 2444, ISSN: 0003-9926 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, BELL LARRY ET AL: "Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia.", XP002237123, Database accession no. PREV199395065748 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, DENKE MARGO A ET AL: "Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men.", XP002237122, Database accession no. PREV199396043148 *
DATABASE WPI Section Ch Week 199351, Derwent World Patents Index; Class B04, AN 1993-408295, XP002237129 *
DATABASE WPI Section Ch Week 199813, Derwent World Patents Index; Class D13, AN 1998-138203, XP002237128 *
DATABASE WPI Section Ch Week 200042, Derwent World Patents Index; Class B05, AN 2000-476630, XP002237125 *
DATABASE WPI Section Ch Week 200054, Derwent World Patents Index; Class B04, AN 2000-572814, XP002237127 *
DATABASE WPI Section Ch Week 200132, Derwent World Patents Index; Class B04, AN 2001-300860, XP002237124 *
DATABASE WPI Section Ch Week 200168, Derwent World Patents Index; Class B04, AN 2001-597454, XP002237126 *
JOURNAL OF NUTRITION, vol. 123, no. 6, 1993, pages 1047 - 1053, ISSN: 0022-3166 *
PATENT ABSTRACTS OF JAPAN vol. 012, no. 482 (C - 553) 15 December 1988 (1988-12-15) *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 431 (C - 0983) 9 September 1992 (1992-09-09) *
TOUSSAINT ET AL: "Effect of Water Containing Calcium and Magnesium Sulfates on the Elimination of Cholesterol in the Rat", ARCHIVES INTERNATIONALES DE PHYSIOLOGIE ET DE BIOCHIMIE, VAILLANT CARMANNE, LIEGE, BE, vol. 96, no. 2, June 1988 (1988-06-01), pages 89 - 100, XP002100566, ISSN: 0003-9799 *

Also Published As

Publication number Publication date
AU2002331279A1 (en) 2003-02-17
DE10135493A1 (de) 2003-01-30
EP1408992A2 (de) 2004-04-21
WO2003011309A2 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
WO2004006858A3 (en) Compounds, compositions, and methods employing same
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
PL1663185T3 (pl) Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
WO2002000227A3 (en) Use of lanthanum compounds for the treatment of bone diseases
WO2003037368A3 (en) Smad7 inhibitors for the treatment of cns diseases
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
YU82602A (sh) Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
SE0101082D0 (sv) Novel use
BR0008603A (pt) Método para tratamento de copd
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
EA200400436A1 (ru) Медикаменты для профилактики и лечения бромидроза
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
WO2003084503A3 (en) P38 kinase inhibitors for treating mucus hypersecretion_
WO2003011309A3 (de) Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
AUPR809001A0 (en) Compositions for the treatment and prevention of plant pathogens
WO2002055096A3 (de) Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
WO2004055001A3 (en) Rabeprazole calcium
IL159511A0 (en) Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VN ZA ZM ZW GH GM KE LS MW MZ SD SZ TZ UG ZM ZW AM

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002767244

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002767244

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载